With Perioperative Pembrolizumab, Event-Free Survival for Ea

With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.

Related Keywords

Stanford University , California , United States , Chicago , Illinois , Stanford , American , Tezepelumab Tezspire , Heather Wakelee , Heathera Wakelee , Astrazeneca , American Society Of Clinical Oncology , Institute In Stanford , Amgen , Stanford University School , Deputy Director , Stanford Cancer , Pharmacy Times , Clinical Oncology , Annual Meeting ,